Driver MutationsNon-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patient...
Most clinically relevant translational advances made in genes involved in lung tumorigenesis namely EML4-ALK fusions, HER2, PIK3CA, AKT, BRAF, MAP2K1, MET mutations and amplifications along with the well established EGFR and KRAS mutations are discussed in the context of NSCLCs. These studies ...
We determined the frequency of driver mutations in a large series of Chinese NSCLC patients. EGFR TKIs might improve the survival outcomes ofEGFR-mutated lung adenocarcinoma patients who experienced disease recurrence. 展开 关键词: non-small cell lung cancer driver mutations ERBB FGFR ...
Background: While there is growing interest in targeted therapy for non-small cell lung cancer (NSCLC) in perioperative settings, data on key oncogenic driver mutations is limited in early-stage NSCLC. This real-world database study aims to evaluate the prevalence of select genomic alterations in...
The genetic mutations that contribute to the transformation of healthy cells into cancerous cells have been the subject of extensive research. The molecular aberrations that lead to cancer development are often characterised by gain-of-function or loss-of-function mutations in a variety of oncogenes...
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer Gefitinib is a valid second-line therapy for previously treated non-small cell lung cancer (NSCLC) patients. The influences of various chemotherapy regimen... JY Wu,CJ Yu,JY ...
For patients with identified driver mutations (e.g., EGFR, ALK, ROS1), targeted therapies remain the first-line treatment. Osimertinib is the preferred option for EGFR mutations. New Driver Alterations: The guidelines now include recommendations for emerging targets like MET and RET, reflecting the...
1 These mutations induce and sustain tumorigenesis, and can be thus referred to as "driver mutations." These cancers are reliant upon the protein product of this gene for their malignant phenotype. In these tumors, targeting this protein, or "Achilles heel" of the cancer, can profoundly ...
driver mutations in epigenetic regulators, providing a mechanistic link between the cancer epigenome and genetic alterations. Oncogenic activating mutations are now known to occur in a number of epigenetic modifiers (i.e.IDH1/2,EZH2,DNMT3A), pinpointing epigenetic pathways that are involved in ...
Missense driver mutations in cancer are concentrated in a few hotspots1. Various mechanisms have been proposed to explain this skew, including biased mutational processes2, phenotypic differences3–6 and immunoediting of neoantigens7,8; however, to our k